# Junta clínica — PT-pseudo_033f1a8e1503 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_033f1a8e1503",
  "pid": "PT-pseudo_033f1a8e1503",
  "task": 1,
  "psa": 5.9,
  "age": 60,
  "months": 1,
  "pirads": "5",
  "psad": 0.199,
  "psav": 1.83,
  "psap": 4.1,
  "vol": 29.71,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.84285355,
  "medhx": "Hypertension, Coronary artery disease, Benign prostatic hyperplasia",
  "meds": "amlodipine, aspirin 80 mg, atorvastatin, metoprolol, tamsulosin",
  "notes": "PSA 5.9 ng/mL. PI-RADS 5. PSAD 0.20. Prostate volume 30 mL. csPCa 0.84.",
  "pmhx": [
    "Hypertension",
    "Coronary artery disease",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "82 kg",
    "height": "184 cm",
    "bmi": "24.2",
    "bp": "113/77 mmHg",
    "hr": "77 bpm",
    "smoking": "Ex-smoker (31 pack-yr, quit 2022)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "12 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Routine monitoring after mpMRI completion and detection of an upward PSA trajectory."
    },
    {
      "s": "History",
      "t": "A 60-year-old retired carpenter who has never married and currently resides with his partner has remained under routine observation since an initial PSA elevation was flagged in April 2022. He walks twenty minutes daily and ceased tobacco use completely in 2022, concluding a thirty-one pack-year smoking history. His pharmacological profile consists of amlodipine, metoprolol, aspirin 80 mg, atorvastatin, and tamsulosin, the latter addressing benign prostatic hyperplasia that yields minor bothersome symptoms (IPSS 7/35). Underlying hypertension and coronary artery disease remain stable. No prior biopsy history has been recorded. Recent outpatient visits covered audiological screening, pulmonary function tests for established COPD, and dermatological evaluation for actinic keratosis. A cholecystectomy performed during his forties represents his only surgical history. He reports no acute complaints or systemic symptoms beyond these managed chronic conditions."
    },
    {
      "s": "Physical examination",
      "t": "DRE reveals a uniformly smooth prostatic contour, free of nodularity or asymmetrical firmness. Systemic assessment shows no acute abnormalities, with cardiovascular and pulmonary signs aligning with his established medical background."
    }
  ],
  "occupation": "retired carpenter",
  "marital": "Never married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Dermatology — actinic keratosis check",
    "Pulmonary function test — known COPD follow-up",
    "Audiology — hearing test"
  ],
  "alcohol": "3 units / week",
  "exercise": "Walking 20 min/day",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_033f1a8e1503
Task: 1

Encounter: Urology - outpatient on 12 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 5.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.199 ng/mL²
  - PSA velocity: 1.83 ng/mL/yr
  - Prior PSA: 4.1 ng/mL
  - Prostate volume: 29.71 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84285355 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Coronary artery disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Coronary artery disease, Benign prostatic hyperplasia
  - Current medication: amlodipine, aspirin 80 mg, atorvastatin, metoprolol, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 5.9 ng/mL. PI-RADS 5. PSAD 0.20. Prostate volume 30 mL. csPCa 0.84.

Vitals: weight 82 kg, height 184 cm, BMI 24.2, BP 113/77 mmHg, HR 77 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2022).

Chief complaint: Routine monitoring after mpMRI completion and detection of an upward PSA trajectory.

History: A 60-year-old retired carpenter who has never married and currently resides with his partner has remained under routine observation since an initial PSA elevation was flagged in April 2022. He walks twenty minutes daily and ceased tobacco use completely in 2022, concluding a thirty-one pack-year smoking history. His pharmacological profile consists of amlodipine, metoprolol, aspirin 80 mg, atorvastatin, and tamsulosin, the latter addressing benign prostatic hyperplasia that yields minor bothersome symptoms (IPSS 7/35). Underlying hypertension and coronary artery disease remain stable. No prior biopsy history has been recorded. Recent outpatient visits covered audiological screening, pulmonary function tests for established COPD, and dermatological evaluation for actinic keratosis. A cholecystectomy performed during his forties represents his only surgical history. He reports no acute complaints or systemic symptoms beyond these managed chronic conditions.

Physical examination: DRE reveals a uniformly smooth prostatic contour, free of nodularity or asymmetrical firmness. Systemic assessment shows no acute abnormalities, with cardiovascular and pulmonary signs aligning with his established medical background.

Patient info: retired carpenter; Never married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 3 units / week; exercise Walking 20 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check; Pulmonary function test — known COPD follow-up; Audiology — hearing test.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.87
  uncertainty  +/- 0.07 epistemic (95% band 0.72-1.00); among patients I cannot tell apart the outcome was 0.56 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = None (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 3 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 60 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 5.9 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 29.71 mL (1% of my signal; from log_vol, vol) · PSA density = 0.199 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.84 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PI-RADS = 5
  important  prior biopsy = None
  noted      age = 60 · DRE = Normal · PSA = 5.9 ng/mL · prostate volume = 29.71 mL · PSA density = 0.199 · comorbidity = 3 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: clear — the rule matched the reading urologist in 24 of 24 labelled cases

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 23 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.54: PI-RADS 5, PSA 5.5, PSAD 0.136, age 61, DRE Normal -> BIOPSY (clear). He wrote: "Biopsy naive PIRADS 5 needs biopsy"
  2. distance 0.79: PI-RADS 5, PSA 7.0, PSAD 0.329, age 63, DRE Normal -> BIOPSY (clear). He wrote: "P5 in a man with rapid increasing PSA"
  3. distance 0.91: PI-RADS 5, PSA 3.7, PSAD 0.116, age 63, DRE Normal -> BIOPSY (clear). He wrote: "P5 in 63 year old man."

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   PI-RADS = 5
  important  age = 60 · PSA = 5.9 ng/mL
  noted      prior biopsy = None · family history = not opened (0 of 91) · DRE = Normal · prostate volume = 29.71 mL · PSA density = 0.199 · comorbidity = 3 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the precedents agree (1.00) and the library is right 92% of the time in this situation out of fold

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 23 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  decisive   PI-RADS = 5
  important  age = 60 · PSA = 5.9 ng/mL
  noted      prior biopsy = None · family history = not opened (0 of 91) · DRE = Normal · prostate volume = 29.71 mL · PSA density = 0.199 · comorbidity = 3 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses using the PI-RADS score to trigger biopsy and the role of MRI in the diagnostic pathway. "a PI-RADS threshold of $\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I note that the guideline treats the PI-RADS score as a trigger for biopsy, whereas EXPERT-STRUCTURED marked PI-RADS as decisive, while the guideline treats it as a threshold. The guideline suggests that for a PI-RADS 5 lesion, biopsy is indicated, which aligns with EXPERT-COHORT's criterion, but the guideline does not account for the patient's prior biopsy status as a decisive factor in the same way EXPERT-STRUCTURED did. The guideline requires the prior biopsy status to be established to determine the appropriate pathway. The guideline needs the prior biopsy status to be established.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: at None the guideline suggests that a PI-RADS $\ge 3$ triggers biopsy, which means the indication stands if the prior biopsy status is None.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: the guideline does not explicitly state a threshold for PSA velocity, but the patient's velocity of 1.83 ng/mL/yr is a factor in the clinical context.
laboratory_results - the PSA density: the guideline suggests that a PSA-D cut-off of $0.15 \text{ ng/mL/cc}$ may be relevant in risk-adapted matrix tables.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case strongly points towards biopsy based on the PI-RADS 5 and the precedent, but we need to establish the prior biopsy status from the previous notes to fully align with the EAU guideline.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Assess the clinical relevance of the PSA velocity of 1.83 ng/mL/yr.
  previous_notes (get_previous_notes) -> Establish the prior biopsy status and any surveillance protocol.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the prior biopsy status to determine the appropriate pathway?
  Q2. Does the radiology_report indicate whether the lesion is compared against an earlier study?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report: Multiparametric MRI Prostate | Amsterdam UMC, AMC | 05 January 2025. The lesion is compared against an earlier study: new. LESION: PI-RADS 5 lesion in the left peripheral zone, size 12 x 9 x 10 mm.
psa_trend: PSA 4.2 (Apr 2022) rising to 3.4 (Sep 2023), then to 5.9 (Jan 2025). The clinical relevance of the PSA velocity of 1.83 ng/mL/yr is noted as a factor in the clinical context.
previous_notes: Prior biopsy: None. Surveillance: Routine observation since an initial PSA elevation was flagged in April 2022.

WHAT I DID NOT OPEN
laboratory_results. I left this closed because the panel data was already summarized in the initial intake, and the specific PSA density value was not explicitly requested by the moderator's questions.

WHAT THIS SUPPORTS
FOR sampling this patient now:
- PI-RADS 5 lesion in the left peripheral zone (from radiology_report).
- Prior biopsy status is None (from previous_notes).
AGAINST sampling this patient now:
- DRE is Normal (from intake notes).

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 5.90 ng/mL over 3 points spanning 33 months; velocity +0.61 ng/mL per year; doubling time about 69 months.
PROJECTION at 6 months: 7.9 ng/mL, conformal 95% band 2.3-27.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 5.9 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.84
  uncertainty  +/- 0.06 epistemic (95% band 0.72-0.96), of which 0.01 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = None (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 5.9 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 29.71 mL (4% of my signal; from log_vol, vol) · PSA density = 0.199 (0% of my signal; from psad_calc) · comorbidity = 3 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.87  ('firm' tier; weight 3.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.84  ('firm' tier, fusion_nolab; weight 4.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents; does not vote)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_3) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           None                         E1:DEC E3:DEC cohort:IMP library:not E2:—            -> noted
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          60                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Normal                       E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          5.9 ng/mL                    E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          29.71 mL                     E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.199                        E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.84                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:DEC library:DEC E2:—            -> decisive
  comorbidity  3 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) have answered the moderator's questions. The prior biopsy status is established as "None" from previous_notes, and the radiology_report indicates the lesion is "new" compared to an earlier study.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of BIOPSY. Specifically, the prior biopsy status being "None" supports the cohort criterion, and the radiology_report confirming a "new" lesion supports the general indication for biopsy.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the prior biopsy status to determine the appropriate pathway? Answered by the registrar: Prior biopsy: None.
Q2. Does the radiology_report indicate whether the lesion is compared against an earlier study? Answered by the registrar: The lesion is compared against an earlier study: new.

WHAT CARRIES WEIGHT, AND WHY
<pirads>: 5: decisive because EXPERT-COHORT marked it decisive, and the guideline suggests PI-RADS $\ge 3$ triggers biopsy. I agree with the PANEL-PROTOCOL's marking of PI-RADS as decisive.
<prior biopsy>: None: decisive because EXPERT-STRUCTURED marked it decisive, and the EAU guideline requires this status to determine the pathway. I agree with the PANEL-PROTOCOL's marking of prior biopsy as decisive.
<psa>: 5.9 ng/mL: important because EXPERT-STRUCTURED marked it important, and the trajectory is rising, which is a clinical factor. I agree with the PANEL-PROTOCOL's marking of PSA as important.
My confidence in the record as it stands is clear.

MY SUGGESTION TO THE CHAIR
The record is in a state to be decided based on the panel's conclusion. The evidence retrieved confirms the conditions under which the PANEL-PROTOCOL reached its decision. I suggest proceeding with biopsy firmly.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

60y/PSA 5.9/PSAD 0.199, biopsy-naive, PIRADS 5 mandates sampling. The high PI-RADS score and elevated PSA density support immediate biopsy. No prior pathology exists to alter this finding.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
